Sales of cancer fighting drugs soared in Canada over the past decade

29 October 2020 - Canada is the only country with a universal health care system without coverage for prescription drugs. ...

Read more →

Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours

8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...

Read more →

Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours

1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada. ...

Read more →

Roche Canada announces FoundationOne Liquid CDx now available in Canada

8 September 2020 - Comprehensive pan-tumour liquid biopsy test analyzes >300 cancer-associated genes and multiple genomic signatures to inform treatment choices. ...

Read more →

Impact of rarity on Canadian oncology health technology assessment and funding

11 August 2020 - The pan-Canadian Oncology Drug Review evaluates new cancer drugs for public funding recommendations.  ...

Read more →

Montreal mother launches desperate plea for help to access experimental cancer treatment

17 May 2020 - Montreal mother launches desperate plea to access experimental cancer treatment in U.S. amid COVID-19 travel restrictions. ...

Read more →

Evaluation of the impact of patient involvement in health technology assessments: a scoping review

8 May 2020 - While involving patients in health technology assessment has become increasingly common and important around the world, little ...

Read more →

'Incredibly upsetting': breast cancer patients dealing with shortage of common drug treatment

12 November 2019 - When Tricia Smith tried to fill her prescription for tamoxifen two weeks ago, she was shocked ...

Read more →

Women living with metastatic breast cancer in British Columbia now have public access to Kisqali

23 October 2019 - Novartis Pharmaceuticals Canada is pleased to announce that British Columbia will now reimburse Kisqali (ribociclib) for eligible ...

Read more →

Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)

9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...

Read more →

Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review

23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...

Read more →

Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer

19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...

Read more →

Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement

12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...

Read more →

Quebec becomes first province to list Lonsurf (trifluridine/tipiracil) for public reimbursement for adult patients with metastatic colorectal cancer

19 August 2019 - Cancer treatment taken orally shown to extend overall survival in patients whose disease has progressed following treatment ...

Read more →

Costing methods applied to cancer

8 August 2019 - Health care is vital in improving quality and length of life.  ...

Read more →